Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care

Clin Neurol Neurosurg. 2020 Oct:197:106203. doi: 10.1016/j.clineuro.2020.106203. Epub 2020 Sep 2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Alemtuzumab / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • Child
  • Coronavirus Infections*
  • Crotonates / therapeutic use
  • Dimethyl Fumarate / therapeutic use
  • Female
  • Fingolimod Hydrochloride / therapeutic use
  • Humans
  • Hydroxybutyrates
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / therapeutic use*
  • Kuwait
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Natalizumab / therapeutic use
  • Nitriles
  • Pandemics*
  • Pneumonia, Viral*
  • Recurrence
  • Rituximab / therapeutic use*
  • SARS-CoV-2
  • Surveys and Questionnaires
  • Telephone
  • Toluidines / therapeutic use
  • Young Adult

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Humanized
  • Crotonates
  • Hydroxybutyrates
  • Immunologic Factors
  • Natalizumab
  • Nitriles
  • Toluidines
  • teriflunomide
  • Alemtuzumab
  • Rituximab
  • Interferon-beta
  • ocrelizumab
  • Dimethyl Fumarate
  • Fingolimod Hydrochloride